Daily Archives: December 1, 2016

Ziprasidone (US brand name Geodon® and generic) is a second-generation (“atypical”) antipsychotic. FDA-approved indications A. As an oral formulation 1. Schizophrenia 2. Acute treatment as monotherapy of manic or mixed episodes associated with bipolar I disorder 3. Maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate B. As an intramuscular injection […]

Lurasidone or Latuda® is a second-generation antipsychotic, manufactured by Sunovion and introduced in the US in 2010 for the acute treatment of schizophrenia. Note: This page and its related pages contain the full text of the chapter on lurasidone (Latuda) in my book, The Latest Antidepressants. This webpage will always have the most up-to-date version of that […]

Iloperidone (US brand name Fanapt®) is a second-generation (“atypical”) antipsychotic. FDA-approved indications Treatment of adults with schizophrenia Dosage Starting: 1 mg twice daily Target: 6–12 mg twice daily (achieved by dose increments of 1–2 mg twice daily) Maximum: 12 mg twice daily (24 mg/day) Please refer to Prescribing Information (see link below) for complete discussion […]

Clozapine (US brand names Clozaril®, Fazaclo® ODT, Versacloz®, and generic) is a second-generation (“atypical”) antipsychotic. Here is basic information about this medication. FDA-approved indications 1. Treatment resistant schizophrenia 2. Reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder Dosage Starting: 12.5 mg once or twice daily, with or without food Titration: Increase the total daily dosage in increments […]

Cariprazine (Vraylar®) is a second-generation (atypical) antipsychotic. Here is basic information about this medication. FDA-approved indications 1. Schizophrenia 2. Acute treatment of manic or mixed episodes associated with bipolar I disorder. Dosage Schizophrenia Starting: 1.5 mg/day Recommended: 1.5–6 mg/day Bipolar Mania Starting: 1.5 mg/day Recommended: 3–6 mg/day Please refer to Prescribing Information (see link below) for […]

The United States Food and Drug Administration (FDA) approved   brexpiprazole (brand name “Rexulti®”) in July 2015 for two indications:   the treatment of schizophrenia and as adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD). Rexulti® is manufactured by Otsuka Pharmaceutical Company Ltd and co-marketed with H. Lundbeck A/S. Pharmacological effects 1. Partial agonist at […]

Asenapine (US brand name Saphris®) is a second-generation (“atypical”) antipsychotic. FDA-approved indications 1. Schizophrenia 2. Acute treatment of manic and mixed episodes associated with bipolar I disorder (monotherapy) 3. Acute treatment of manic and mixed episodes associated with bipolar I disorder (adjunctive to lithium or valproate) Dosage Schizophrenia – acute treatment in adults Starting: 5 […]

Aripiprazole (US brand name Abilify® and generic Aripiprix, zolonda) is a second-or third generation (atypical) antipsychotic. FDA-approved indications A. Oral 1. Schizophrenia 2. Acute treatment of manic and mixed episodes associated with bipolar I disorder 3. Adjunctive treatment of major depressive disorder 4. Irritability associated with autistic disorder 5. Treatment of Tourette’s disorder B. Injectable […]